July 28, 2022
Davis Sherman, PhD, Hans W. Vahlteich Professor of Medicinal Chemistry

Written By: Emily Kagey, Life Sciences Institute

An international team of researchers has developed a method for altering one class of antibiotics, using microscopic organisms that produce these compounds naturally. 

The findings, published July 25 in Nature Chemistry, could lead to more efficient production of antibiotics that are effective against drug-resistant bacteria.

The team started with a microorganism that is genetically programmed to produce the antibiotic erythromycin. Scientists from the Institute of Organic Chemistry and Chemical  

Biology at Germany’s Goethe University wondered if the system could be genetically altered to assemble the antibiotic with one additional fluorine atom, which can often improve pharmaceutical properties.

“We had been analyzing fatty acid synthesis for several years when we identified a part of a mouse protein that we believed could be used for directed biosynthesis of these modified antibiotics, if added to a biological system that can already make the native compound,” said Martin Grininger, professor for biomolecular chemistry at Goethe University.

Working with the lab of David Sherman at the University of Michigan, which specializes in this biological assembly system, the team used protein engineering to replace one part of the system’s native machinery with the functionally similar mouse gene.

“It’s like taking one engine part out of a Mercedes and putting it into a Porsche to make a better hybrid engine. You get a Porsche engine that can do new things and works even better,” said Sherman, a faculty member at the U-M Life Sciences Institute and professor of medicinal chemistry in the College of Pharmacy.

“We can now take advantage of this protein engineering to make new compounds that have this very desirable fluorine atom, which chemists have been struggling to add to macrolide antibiotics for a long time.”

The reason this added fluorine atom is so desirable is that it changes not only the structure of the final product, but the product’s ability to kill bacteria and work safely in patients.

Erythromycin works by binding to and blocking the activity of the bacterial ribosome, which is essential for bacteria to survive. Some bacteria have evolved ways to prevent this binding, making them resistant to treatment with antibiotics. Altering the antibiotic’s structure with a fluorine atom overcomes that evolutionary advantage, restoring the compound’s ability to fight bacteria.

While chemists have developed methods for adding the fluorine synthetically, the process is arduous and requires the use of toxic chemical reagents. The new biosynthetic method developed by the researchers from Goethe University and U-M overcomes those challenges.

“It’s a very exciting development, because we can bypass all the time-consuming synthetic steps and dangerous chemicals,” Sherman said. “We have shown that we can basically reprogram an organism to make the fluorinated product directly.”

The researchers emphasize that the fluorinated compounds are still a few years away from being available in the clinic. But the findings offer a more efficient path forward for developing new antibiotics, and even antivirals and anti-cancer medications.

“Our approach has been proven successful on a small set of antibiotics, but it could ultimately be used to develop a wide range of pharmaceuticals with minimal use of toxic chemicals and by-products,” Grininger said.

This research was supported by the Volkswagen Foundation, the LOEWE programme of the state of Hesse and the National Institutes of Health.

Study: Chemoenzymatic synthesis of fluorinated polyketides (DOI: 10.1038/s41557-022-00996-z)

Other study authors are: Alexander Rittner, Mirko Joppe, Lara Maria Mayer, Simon Reiners, Elia Heid and Dietmar Herzberg of the Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Germany; and Jennifer Schmidt of the University of Michigan Life Sciences Institute.